Eli Lilly opens clinical data to medical researchers
- Eli Lilly will share clinical trial data with medical researchers who have approved proposals.
- Available information will include data from phase II-phase IV studies.
- Several large pharma companies are involved in this initiative. The goal is to support clinical research efforts by making data more transparent.
The information that Eli Lilly will make available will include data that was used to gain regulatory approval in studies submitted for approval on or after 1999. The focus is clinical and not preclinical data, as the goal is to support drugs that have already passed that critical stage of development. Data will be available for studies that gained approval in the U.S. and/or the European Union. For researchers who have specific proposals, gaining access to information that shows a regulatory pathway has immense value. Other companies involved in this initiative include GSK, Novarits, Boehringer Ingelheim and VIV Healthcare.